Aytu Biopharma (AYTU) Q1 2025 earnings summary

Executive summary

• Achieved first-ever positive net income of $1.5 million in Q1 FY2025, reversing a prior-year net loss of $8.1 million, and marked the sixth consecutive quarter of positive adjusted EBITDA at $1.9 million, reflecting successful transformation and operational optimization.

• Completed the divestiture of the Consumer Health business in July 2024, now focusing on prescription pharmaceuticals, primarily ADHD and pediatric products, and implemented organizational changes to reduce operating expenses by at least $2 million annually.

• ADHD and pediatric portfolios showed positive trends, with ADHD scripts above pre-shortage baselines and pediatric revenue rebounding sequentially after payer-driven declines.

• Leadership transition included the appointment of Ryan Selhorn as CFO and the departure of Mark Oki, alongside other executive changes to support the company’s turnaround.

• New international agreements were signed for ADHD products in Israel and Canada, expanding future market reach.

Financial highlights

• Net revenue was $16.6 million in Q1 FY2025, down from $17.8 million year-over-year, mainly due to lower pediatric sales; ADHD revenue was $15.3 million (up from $15.1 million), pediatric revenue $1.3 million (down from $2.6 million but up sequentially from $0.8 million).

• Gross profit was $12.0 million (72% margin), compared to $13.0 million (73%) in the prior year.

• Operating expenses (excluding amortization and restructuring) fell to $11.2 million, driven by reductions in marketing, contracted services, and headcount.

• Net income benefited from a $2.9 million gain on derivative warrant liabilities due to a decrease in stock price.

• Cash and cash equivalents stood at $20.1 million at quarter end, flat sequentially.

Outlook and guidance

• Management expects to accelerate profitability through continued revenue growth, further $2 million annual reduction in operating expenses, and optimization efforts.

• Normalized gross margins anticipated by Q1 FY2026 as higher-cost inventory is sold through.

• No need for additional equity capital; seasonal needs covered by expanded credit agreements.

• Anticipate material royalty revenue from out-licensing ADHD brands internationally within 18–24 months.

• Inflationary pressures and supply chain disruptions are expected to persist through fiscal 2025.